

Heterogeneity and prognosis of single organ metastases in gastric cancer

Qian-Wen Zhao^{1#}, Zheng Quan^{2#}, Shan-Shan Liu¹, Yu-Dan Wang², Hao-Nan Guo¹

¹Department of Clinical Laboratory, The Affiliated Hospital of Guilin Medical University, Guilin, China; ²Department of Oncology Surgery, Xi'an No. 3 Hospital, The Affiliated Hospital of Northwest University, Xi'an, China

Contributions: (I) Conception and design: HN Guo; (II) Administrative support: HN Guo; (III) Provision of study materials or patients: HN Guo, Z Quan, QW Zhao; (IV) Collection and assembly of data: Z Quan, QW Zhao, YD Wang; (V) Data analysis and interpretation: QW Zhao, Z Quan, SS Liu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Hao-Nan Guo, PhD. Department of Clinical Laboratory, The Affiliated Hospital of Guilin Medical University, No. 15 Lequn Road, Guilin 541001, China. Email: guohaonan@glmc.edu.cn.

Background: While single organ metastases generally present a more optimistic prognosis compared to multiple metastases, the influence of the specific organ site for single organ metastases on prognosis remains undetermined. This retrospective study aimed to investigate the prognostic differences in late-stage gastric cancer with single organ metastasis.

Methods: Data for patients diagnosed with gastric cancer were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database for survival analysis, covering years spanning from 2010 to 2016. Furthermore, Kaplan-Meier survival curves and Cox regression were utilized to analyze overall survival (OS) and disease-specific survival (DSS). Additionally, given the impact of confounders and bias on the results, prognosis was further analyzed using propensity score matching (PSM) and floating absolute risk methods.

Results: A cohort comprising 4,297 patients diagnosed with gastric cancer and exhibiting single organ metastasis was hereby enrolled. Liver metastasis was the most common (71% of the total), while brain metastasis accounted for the least (1.7% of the total). Compared to other metastases, patients with bone metastasis presented the worst OS [hazard ratio (HR), 1.319; 95% confidence interval (CI): 1.207–1.442; P<0.001], and this remained consistent even upon the application of floating absolute risk (HR, 1.10; 95% CI: 1.01–1.20) and PSM methods (HR, 1.187; 95% CI: 1.053–1.339; P=0.005). In addition, subgroup analysis and interaction tests of OS revealed an interaction between age (P=0.02), histological type (P=0.002), and bone metastasis.

Conclusions: In patients with single organ metastasis of gastric cancer, the prognosis varies by the metastatic site, with bone metastasis presenting the poorest outcome. Overall, this study forges a foundation for further research on the mechanisms and patterns of different metastatic sites in gastric cancer and informs treatment strategies.

Keywords: Gastric cancer; floating absolute risk; prognostic differences; single organ metastases; propensity score matching (PSM)

Received: 22 January 2024; Accepted: 01 August 2024; Published online: 25 September 2024. doi: 10.21037/tgh-24-11 View this article at: https://dx.doi.org/10.21037/tgh-24-11

Introduction

Gastric cancer poses a major global health challenge, ranking as the fifth most common malignancy worldwide, with over one million new cases annually (1). It is also the third leading cause of cancer-related deaths (2). Gastric cancer exhibits distinct regional variations, with higher incidence rates observed in East Asia and Eastern Europe compared to Northern Europe and North America (3). One major contributing factor to the high mortality rate of gastric cancer is the late-stage diagnosis, often characterized by diminished therapeutic possibilities and advanced tumor metastasis, hastening disease progression and even leading to patient death (4). The European Society for Medical Oncology (ESMO) does not recommend gastric resection for metastatic gastric cancer unless it is performed as palliative surgery (5). Meanwhile, gastric cancer usually develops multiple metastases, with the peritoneum and lymph nodes being the most common sites, followed by the liver (6). Multiple metastases often indicate a more aggressive cancer, while single organ metastases may be associated with a better prognosis in certain types of cancer. Examples include bone metastases in breast cancer (7), lymph node metastases in colon cancer (8), liver metastases in gastric adenocarcinoma (AC) (9), brain metastases in non-small cell lung cancer (10), and metastatic uroepithelial carcinoma (11). Besides, it should be particularly noted that these evaluations are based on objective medical research and should be presented as such. Furthermore, studies have demonstrated considerable heterogeneity in cancer

Highlight box

Key findings

• The prognosis for gastric cancer patients with single organ metastasis varies by the metastatic site, and bone metastasis turns to have the worst prognosis.

What is known and what is new?

- This study made the initial attempt to investigate the prognostic differences of single lung, liver, bone, and brain metastases in gastric cancer.
- Hazard ratios and floating absolute risk hazards were utilized to demonstrate the independent prognostic variations of different metastatic sites in gastric cancer.

What is the implication, and what should change now?

• This discovery can assist physicians in more accurately estimating patients' prognoses, enable the patients to better understand their disease status, and improve their quality of life.

Translational Gastroenterology and Hepatology, 2024

metastasis across different organs. For instance, peritoneal metastasis is the most common in gastric cancer (6), while breast cancer tends to develop bone metastasis (12). Even within the context of identical single-site metastases, variations arise in the metastatic distribution from primary tumors of the same type. Breast cancer's bone metastases tend to concentrate in the thoracic spine, in contrast to lung cancer's bone metastases, which disseminate more extensively (13). The microenvironment of metastatic cancer differs with the change of metastatic sites. For instance, breast cancer can impact and alter the microenvironment of the bone and lung, thereby promoting cancer metastasis. Similarly, the liver microenvironment may also affect breast cancer metastasis (14). In conclusion, while metastatic cancers from various organs exhibit evident heterogeneity, differences in single organ metastasis of gastric cancer remain unclarified. Indeed, the distant metastasis of gastric cancer has been inadequately studied in terms of prognostic differences between various metastatic sites. Previous research has primarily focused on a generalized analysis of single and combined metastases. Particular attention has been paid to metastatic cancers at specific locations, such as bone metastasis (15) and liver metastasis (16), as well as on single organ metastases of specific tumor types (11,12). These studies have significantly enhanced public understanding of regulatory mechanisms and coincided with rapid advancement in therapeutic strategies and the proliferation of clinical trials. Nevertheless, the examination and comparison of prognostic differences across diverse metastatic sites have been overlooked to certain extent, warranting further investigation into the prognostic differences of single lung, liver, bone, and brain metastases in the era of precision medicine.

Currently, treatment of advanced gastric cancer encompasses not only conventional cytotoxic chemotherapy but also witnesses a rising integration of targeted therapies and immunotherapeutic agents (17). Due to the varied prognoses associated with various treatments, physicians must exercise meticulous judgment in their therapeutic approach selection, which may also impact patients' treatment preferences, particularly in developing countries. A Swedish-based study revealed that the liver was the most common metastatic site in gastric cancer (accounting for 48% of all metastases), while bone metastasis only accounted for 12% (18). In addition to metastatic sites, the study of metastatic burden, i.e., the number of metastases, remains limited (18). Thus, to date, consensus regarding the prognostic differences of single organ metastases at different sites has not been reached. Both limited patient cases and the challenge of conducting single-center studies have contributed to this lack of consensus. Currently, observational studies have been central in investigating metastatic gastric cancer. However, they are prone to potential biases stemming from the arbitrary selection of control groups. To this end, propensity score matching (PSM) was utilized to match patients, and floating absolute risks were employed to compare relative risks across various exposure levels, effectively mitigating the impact of bias on the study outcomes. The prognosis of cancer metastasis was found to be impacted by various factors, including the stage and size of the primary tumor at the time of diagnosis (2,19) with pathological staging (20), as well as the treatment modality. These factors should be further explored in gastric cancer patients with single metastasis.

In this study, the prognostic differences between different metastatic sites were discussed, and the impact of these single organ metastases was delved into using methods of PSM and adjusted absolute risk. The Surveillance, Epidemiology, and End Results (SEER) database was systematically reviewed to provide evidence on the prognostic differences of single organ metastases in gastric cancer and to explore potential underlying mechanisms for these differences. The primary objective of this study is to investigate the prognostic differences among various single organ metastases in late-stage gastric cancer. We present this article in accordance with the STROBE reporting checklist (available at https://tgh.amegroups.com/article/ view/10.21037/tgh-24-11/rc).

Methods

Study population

This study is a retrospective population-based study. Patient information recorded in the SEER database from 2010 to 2016 was collected. According to the study objectives, patients with pathological diagnosis and type of AC [International classification of diseases for oncology, third edition, histological codes: 8140 to 8145, 8210 to 8211, 8220 to 8221, and 8260 to 8263 for AC, 8480 and 8481 for mucinous AC (MAC), 8490 for signet ring cell carcinoma (SRCC)] were selected. Those having died within one month of diagnosis or those with unknown survival status were excluded. Besides, the SEER*Stat software (version 8.3.8) was utilized to extract the information needed, including the age, gender, race, marital status, time of diagnosis, clinical stage of American Joint Commission on Cancer, treatment modality (radiotherapy, surgery), pathological type, pathological grade, primary site, single or multiple lesions, number of malignant tumors, tumor metastases, and survival time [include overall survival [OS] and disease-specific survival (DSS)]. In order to minimize biases, patients with distant lymph nodes or peritoneal metastases were further excluded, and only those with specific single metastases (bone, brain, liver, and lung) were finally included. The specific patient inclusion process is presented in Figure S1. Data collection was conducted by Q.W.Z. and Z.Q. jointly from January to May 2022.

The Ethics Committee of The Affiliated Hospital of Guilin Medical University waived the requirement for formal Institutional Review Board approval and informed consent, given its use of anonymous data and supplementary information obtained from individuals. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

PSM method

Herein, the effect of confounding factors was controlled by performing "*post-hoc* randomization" through PSM. Matching factors included covariates such as gender, age, and stage, with a 1:1 variable ratio and a caliper value set at 0.02. The "nearest" method within the "MatchIt" package in R was employed for this process (8). A Chi-squared test of P>0.05 and a standardized mean difference <0.1 in the baseline data table were considered balanced between the two groups.

Statistical analysis

Normality and variance Chi-squared were assessed before performing comparisons between groups, and used *t*-tests or Wilcoxon tests were then conducted. For patients with missing data, we handled the missing values by creating dummy variables. The R (https://www.r-project.org, R version 4.1.1) statistical software was hereby used. Besides, Kaplan-Meier survival curves were employed to exhibit the variation in survival rates between different groups (median survival time represents the survival time at 50%), and logrank tests were carried out to examine the significance of survival rates between the groups, with the survival R package used for analysis (9). Furthermore, univariate and multivariate Cox regression models were adopted to explore factors affecting patient prognosis. Following

Page 4 of 14

Translational Gastroenterology and Hepatology, 2024

that, subgroup Cox regression analysis was performed, and likelihood ratio tests were conducted to analyze the interaction between metastatic sites and other covariates. The "forestplot" package was utilized to draw forest plots for the Cox regressions (10). In comparing the prognostic differences between single lung, liver, bone, and brain metastases of gastric cancer, the liver metastases were used as control, and floating absolute risk method was employed. The floating absolute risk was used to compare the relative risk between different levels of multilevel exposure factors, thus reducing the bias caused by the arbitrary selection of controls. All statistical tests were two-sided, with P<0.05 considered statistically significant.

Results

Baseline characteristics of the study patients

Finally, a total of 4,297 patients with gastric AC were hereby identified as the final study cohort. The predominant sites of single metastases included liver metastases affecting 3,054 patients, followed by bone metastases in 669 patients, lung metastases in 501 patients, and brain metastases in 73 patients. The longest followup period was 81 months, with a median follow-up time of 5 months. Among the different metastasis groups, the median survival of brain metastasis was the shortest, being only four months, and the comparison between groups was statistically significant (P<0.001). In addition, the age groups of metastases also differed among sites, except for brain metastases, where patients aged ≤ 60 years were the least represented. Notably, the highest proportion of patients with liver metastases fell into the age group ≥71 years old, comprising 1,243 patients, which represents 40.7% of all instances of liver metastases and a substantial 28.9% of all patients with a single metastasis. Additional details of each group are shown in Table 1.

Survival analysis of different single metastatic lesions in gastric cancer

Kaplan-Meier curves were hereby plotted to clarify the survival curves for different metastatic sites (*Figure 1*), and median survival times and 95% confidence intervals (CI) were calculated (Table S1). We observed an all-cause mortality rate of 67.9%. The survival times of patients with metastases differed between all-cause and disease-specific deaths (P<0.001), with bone metastasis patients experiencing

the poorest prognosis (Figure 1).

Additionally, Cox proportional risk models were established to examine factors associated with survival. The results revealed that bone metastases (vs. liver metastases) were significantly associated with reduced OS in patients in a univariate regression analysis [hazard ratio (HR), 1.319; 95% CI: 1.207–1.442; P<0.001] (Figure S2), while the brain (P=0.88) and lung metastases (P=0.75) were not significantly associated with patients' OS. Similar results were also observed in the DSS (*Figure 2*). When adjusting all variables for multivariate regression analysis, no significant association between bone metastases and patients OS relative to liver metastases was observed (HR, 1.1; 95% CI: 0.998–1.214; P=0.05). However, there existed a significant association with patients DSS (HR, 1.181; 95% CI: 1.055–1.323; P=0.004). Additional results are shown in *Figure 2*.

Table 2 presents the HR and corresponding 95% CI, with bone metastases being significantly associated with reduced OS in patients (HR, 1.10; 95% CI: 1.01–1.20). However, brain and lung metastases were not significantly associated with OS in patients. The application of DSS as an outcome indicator yielded similar results (HR, 1.18; 95% CI: 1.07–1.30).

Subgroup analysis and interaction of bone metastases from gastric AC

To explore possible interactions, subgroup analysis and interaction testing of metastatic sites were conducted (bone metastases vs. other metastases, Figure 3). In the subgroup analysis, bone metastases were significantly associated with reduced OS in patients in the ≤ 60 and 61–70 years age subgroups (≤60 years: HR, 1.482; 95% CI: 1.29-1.702; 61-70 years: HR, 1.548; 95% CI: 1.312-1.825). In the ≥ 71 years age subgroup, bone metastases were not significantly associated with patients OS (P=0.77). Furthermore, there was an interaction between bone metastases and OS in the \geq 71 years group (vs. \leq 60 years group) (P=0.02), but not in the 61-70 years group (vs. \leq 60 years group) (P=0.69). Additionally, tumor pathology type emerged as an interacting element with bone metastasis. The findings revealed that the association between bone metastasis and prognosis was not statistically significant in the MAC or SRCC (MAC/SRCC) subgroup compared to the AC subgroup (HR, 0.997; 95% CI: 0.844-1.177; P for interaction =0.002). In the subgroup with DSS as the outcome, interactions were detected between age (P=0.003), divorced/separated (P=0.04), chemotherapy (P=0.001), and

Variables	Total (n=4,297)	Met.bone (n=669)	Met.brain (n=73)	Met.liver (n=3,054)	Met.lung (n=501)	Р
Sex						<0.001
Female	1,264 (29.4)	239 (35.7)	17 (23.3)	841 (27.5)	167 (33.3)	
Male	3,033 (70.6)	430 (64.3)	56 (76.7)	2,213 (72.5)	334 (66.7)	
Race						<0.001
Black	609 (14.2)	61 (9.1)	5 (6.8)	487 (15.9)	56 (11.2)	
Others	550 (12.8)	105 (15.7)	7 (9.6)	376 (12.3)	62 (12.4)	
White	3,138 (73.0)	503 (75.2)	61 (83.6)	2,191 (71.7)	383 (76.4)	
Marital						0.53
Divorced/separated	449 (10.4)	66 (9.9)	9 (12.3)	315 (10.3)	59 (11.8)	
Married	2,513 (58.5)	382 (57.1)	41 (56.2)	1,803 (59)	287 (57.3)	
Single/unmarried	666 (15.5)	125 (18.7)	11 (15.1)	453 (14.8)	77 (15.4)	
Widowed/unknown	669 (15.6)	96 (14.3)	12 (16.4)	483 (15.8)	78 (15.6)	
Year of diagnosis						0.32
2010	572 (13.3)	78 (11.7)	3 (4.1)	419 (13.7)	72 (14.4)	
2011	647 (15.1)	89 (13.3)	13 (17.8)	479 (15.7)	66 (13.2)	
2012	633 (14.7)	113 (16.9)	13 (17.8)	424 (13.9)	83 (16.6)	
2013	671 (15.6)	104 (15.5)	13 (17.8)	474 (15.5)	80 (16.0)	
2014	673 (15.7)	100 (14.9)	13 (17.8)	478 (15.7)	82 (16.4)	
2015	693 (16.1)	119 (17.8)	13 (17.8)	483 (15.8)	78 (15.6)	
2016	408 (9.5)	66 (9.9)	5 (6.8)	297 (9.7)	40 (8.0)	
AJCC T stage						0.002
T0-2	973 (22.6)	133 (19.9)	14 (19.2)	693 (22.7)	133 (26.5)	
T3-4	1,201 (27.9)	170 (25.4)	15 (20.5)	862 (28.2)	154 (30.7)	
Tx & unknown	2,123 (49.4)	366 (54.7)	44 (60.3)	1,499 (49.1)	214 (42.7)	
AJCC N stage						0.69
N0-1	2,883 (67.1)	440 (65.8)	46 (63)	2,054 (67.3)	343 (68.5)	
N2-3	405 (9.4)	57 (8.5)	7 (9.6)	297 (9.7)	44 (8.8)	
Nx	1,009 (23.5)	172 (25.7)	20 (27.4)	703 (23)	114 (22.8)	
Chemotherapy						0.53
No	1,478 (34.4)	228 (34.1)	29 (39.7)	1,038 (34.0)	183 (36.5)	
Yes	2,819 (65.6)	441 (65.9)	44 (60.3)	2,016 (66.0)	318 (63.5)	
Surgery						0.003
No/unknown	3,944 (91.8)	637 (95.2)	65 (89.0)	2,780 (91.0)	462 (92.2)	
Yes	353 (8.2)	32 (4.8)	8 (11.0)	274 (9.0)	39 (7.8)	

Table 1 Baseline information of all patients

Table 1 (continued)

Page 6 of 14

Table 1 (continued)

Translational Gastroenterology and Hepatology, 2024

Variables	Total (n=4,297)	Met.bone (n=669)	Met.brain (n=73)	Met.liver (n=3,054)	Met.lung (n=501)	Р
Radiation						<0.001
No/unknown	3,369 (78.4)	422 (63.1)	22 (30.1)	2,549 (83.5)	376 (75.0)	
Yes	928 (21.6)	247 (36.9)	51 (69.9)	505 (16.5)	125 (25.0)	
Histological type						<0.001
AC	3,084 (71.8)	347 (51.9)	47 (64.4)	2,376 (77.8)	314 (62.7)	
MAC/SRCC	650 (15.1)	255 (38.1)	17 (23.3)	248 (8.1)	130 (25.9)	
Others [†]	563 (13.1)	67 (10.0)	9 (12.3)	430 (14.1)	57 (11.4)	
Grade						<0.001
I–II	1,157 (26.9)	63 (9.4)	22 (30.1)	958 (31.4)	114 (22.8)	
III–IV	2,303 (53.6)	459 (68.6)	37 (50.7)	1,526 (50)	281 (56.1)	
Unknown	837 (19.5)	147 (22.0)	14 (19.2)	570 (18.7)	106 (21.2)	
Primary site						<0.001
Antrum/pylorus	674 (15.7)	92 (13.8)	3 (4.1)	512 (16.8)	67 (13.4)	
Body	377 (8.8)	68 (10.2)	3 (4.1)	261 (8.5)	45 (9.0)	
Cardia/fundus	1,924 (44.8)	242 (36.2)	52 (71.2)	1,408 (46.1)	222 (44.3)	
Greater curvature	127 (3.0)	21 (3.1)	1 (1.4)	94 (3.1)	11 (2.2)	
Lesser curvature	256 (6.0)	37 (5.5)	3 (4.1)	188 (6.2)	28 (5.6)	
NOS	641 (14.9)	153 (22.9)	8 (11.0)	390 (12.8)	90 (18)	
Overlap	298 (6.9)	56 (8.4)	3 (4.1)	201 (6.6)	38 (7.6)	
Numbers of sites						0.92
1	3,459 (80.5)	533 (79.7)	58 (79.5)	2,462 (80.6)	406 (81.0)	
≥2	838 (19.5)	136 (20.3)	15 (20.5)	592 (19.4)	95 (19.0)	
Age (years)						<0.001
61–70	1,251 (29.1)	184 (27.5)	30 (41.1)	901 (29.5)	136 (27.1)	
≤60	1,399 (32.6)	294 (43.9)	27 (37)	910 (29.8)	168 (33.5)	
≥71	1,647 (38.3)	191 (28.6)	16 (21.9)	1,243 (40.7)	197 (39.3)	
Survival months	5 [2, 12]	5 [2, 9]	4 [2, 11]	6 [2, 12]	6 [2, 12]	<0.001
OS						0.03
Alive	548 (12.8)	65 (9.7)	13 (17.8)	409 (13.4)	61 (12.2)	
Dead	3,749 (87.2)	604 (90.3)	60 (82.2)	2,645 (86.6)	440 (87.8)	
DSS						0.40
Alive	1,378 (32.1)	198 (29.6)	27 (37.0)	990 (32.4)	163 (32.5)	
Dead	2,919 (67.9)	471 (70.4)	46 (63.0)	2,064 (67.6)	338 (67.5)	

Data are presented as n (%) or median [Q1, Q3].[†], pathological types include mucin-producing adenocarcinoma, adenocarcinoma in tubulovillous adenoma, papillary adenocarcinoma, adenocarcinoma in multiple adenomatous polyps, tubular adenocarcinoma, adenocarcinoma, intestinal type, superficial spreading adenocarcinoma, linitis plastica. AJCC, American Joint Commission on Cancer; AC, adenocarcinoma; MAC, mucinous adenocarcinoma; SRCC, signet ring cell carcinoma; NOS, not otherwise specified; OS, overall survival; DSS, disease-specific survival; Met., metastasis; Q1, 25th quartile; Q3, 75th quartile.



Figure 1 Survival curves of different metastatic sites of gastric cancer. Different colors represent different metastatic sites. Survival curves for OS (A) and DSS (B) were plotted using the Kaplan-Meier method. DSS, disease-specific survival; Met., metastasis; OS, overall survival.

the number of tumorigenesis (P=0.006) and bone metastases.

Analysis of prognostic differences among different metastases after PSM

PSM was hereby used to correct confounding factors between groups, including age, sex, race, primary site, T-stage, pathological grade, pathological type, radiotherapy, and surgical treatment. Finally, a cohort of 605 sample size pairs were generated. Table S2 shows the baseline information before and after PSM. Following PSM matching, the data distribution between groups became homogeneous. Figure S3 shows the results of the post-matching equilibrium test. The histogram exhibited good symmetry between the liver metastasis and lung/bone/brain metastasis groups after matching, presenting a well-balanced distribution of covariates between the two groups.

After PSM, the relationship between each factor and

Page 8 of 14

Translational Gastroenterology and Hepatology, 2024

Characteristics	n(%)	Adj.HR (95%CI)	for OS	5		P value	Characteristics	Adj.HR (95%CI) f	or DSS		P value
Age(ref=Age <60)		# / / /					Age(ref=Age <6	0)			
61~70	1251(29.1)	1.093(1.004-1.189)			▶ ● ● ●	0.04	61~70	1.055(0.962-1.157)			0.25
Age >71	1647(38.3)	1.185(1.088-1.291)			! 	< 0.001	Age >71	1.181(1.074-1.298)			< 0.001
Sex(ref=Female)	()						Sex(ref=Female))			
Male	3033(70.6)	1.01(0.938 - 1.088)			++++	0.78	Male	0.993(0.913-1.08)			0.86
Race(ref=White)		(Ĩ		Race(ref=White)		Ī	
Black	609(14.2)	1.032(0.937 - 1.137)			••••	0.52	Black	, 1 054(0 945–1 176)			0.34
Others	550(12.8)	0.96(0.867-1.063)				0.43	Others	0.972(0.868-1.088)			0.61
Marital(ref=Marrie	od)	0100(01007 11000)			Ĩ.		Marital(ref=Mar	ried)		ī	0.01
Divorced/Separated	449(10.4)	1 069(0 959-1 192)				0.22	Divorced/Separate	d1.065(0.941 - 1.205)			0.31
Single/Unmarried	666(15.5)	1.159(1.055-1.273)			1	0.002	Single/Unmarried	1 164(1 05-1 291)			0.004
Widowed/Others	669(15.6)	0.882(0.8-0.972)				0.01	Widowed/Others	0.902(0.805 - 1.01)		-	0.07
Vear of diagnosis(r.	of=2010)	0.002(0.0 0.972)					Vear of diagnosis	(ref=2010)			0.07
2011	647(15.1)	0.978(0.871-1.098)				0.70	2011	1.009(0.884 - 1.151)			0.90
2011	633(14.7)	$0.978(0.871 \ 1.098)$				0.10	2011	0.020(0.814 - 1.06)			0.27
2012	671(15.6)	$0.908(0.808 \ 1.021)$				0.09	2012	$0.929(0.314 \ 1.00)$ 0.906(0.794 - 1.033)			0.12
2013	672(15.7)	$0.903(0.803 \ 1.010)$				0.09	2013	$0.900(0.794 \ 1.033)$			0.15
2014	(0)(15.7)	0.903(0.803 - 1.010)				0.02	2014	0.917(0.802 - 1.048)			0.20
2015	400(0.5)	0.8/1(0.7/2-0.982)				< 0.02	2015	0.883(0.772 - 1.014)			0.07
2016	408(9.5)	0.694(0.578-0.834)			- !	< 0.001	2016	0.754(0.612-0.929)			0.008
Primary site(ref=C:	ardia/Fundi	1 S)				0.26	Primary site(ref=	Cardia/Fundus)		1	0.25
Antrum/Pylorus	6/4(15./)	1.06(0.957-1.175)				0.20	Antrum/Pylorus	1.05/(0.94-1.188)			0.35
Body	3//(8.8)	1.13(0.999–1.279)				0.05	Body	1.09(0.945-1.257)		1	0.23
Greater curvature	127(3)	1.176(0.964–1.435)			•	0.11	Greater curvature	1.254(0.995-1.581)			0.05
Lesser curvature	256(6)	1.033(0.893-1.194)				0.66	Lesser curvature	0.981(0.83-1.159)		••••	0.82
NOS	641(14.9)	1.187(1.073-1.314)			i ⊷ ⊶•	< 0.001	NOS	1.212(1.082-1.357)			< 0.001
Overlap	298(6.9)	1.345(1.179–1.536)			. –	≤ 0.001	Overlap	1.373(1.184–1.593)		I 🕶	< 0.001
AJCC.T(ref=T0-2)					-	0.16	AJCC.T(ref=T0-	2)			
T3-4	1201(27.9)	1.068(0.973-1.172)			+• •	0.16	T3-4	1.117(1.005-1.242)		•••	0.04
Tx&Unknown	2123(49.4)	1.098(1.007-1.197)				0.03	Tx&Unknown	1.159(1.05-1.278)		100	0.003
AJCC.N(ref=N0-1))				!		AJCC.N(ref=N0-	-1)			
N2-3	405(9.4)	1.05(0.932-1.184)			• - •••	0.42	N2-3	0.998(0.87-1.145)		•••	0.98
Nx	1009(23.5)	1.193(1.083-1.315)			i 🛏 🖬	< 0.001	Nx	1.149(1.029-1.282)		101	0.01
Grade(ref=I~II)					!		Grade(ref=I~II)			!	
III~IV	2303(53.6)	1.34(1.237-1.451)			••	⊨ < 0.001	III~IV	1.351(1.233-1.481)			< 0.001
Unknown	837(19.5)	1.181(1.07-1.304)			i 🛏	< 0.001	Unknown	1.188(1.062-1.329)		jee j	0.003
Radiation(ref=No/U	J nknown)				I I		Radiation(ref=No	/Unknown)		1	
Yes	928(21.6)	1.139(1.049-1.237)				0.002	Yes	1.158(1.055-1.271)		!	0.002
Chemotherapy(ref=	=No)				÷		Chemotherapy(re	ef=No)			
Yes	2819(65.6)	0.362(0.337-0.39)			i	< 0.001	Yes	0.348(0.319-0.378)		i	< 0.001
Surgery(ref=No/Un	known)						Surgery(ref=No/U	J nknown)		!	
Yes	353(8.2)	0.521(0.454-0.597)				< 0.001	Yes	0.482(0.411-0.565)	•	•	< 0.001
Histological type(re	f=AC)				i		Histological type(ref=AC)		i	
MAC/SRCC	650(15.1)	1.131(1.023-1.25)			••••	0.01	MAC/SRCC	1.051(0.938-1.178)			0.39
Others	563(13.1)	0.94(0.85-1.039)			•••• <u>+</u> •	0.22	Others	0.871(0.775-0.979)			0.021
Numbers of sites(re	f=1)				i		Numbers of sites(ref=1)		i	
>2	838(19.5)	0.885(0.813-0.963)			+ -I	0.005	>2	0.057(0.043-0.076)		1	< 0.001
- Met.type(ref=Met.l	iver)				!			t.liver)		!	
Met.bone	669(15.6)	1.1(0.998 - 1.214)			—	0.05	Met.bone	1.181(1.055 - 1.323)			0.004
Met.brain	73(1.7)	1.027(0.789-1.337)				0.84	Met.brain	0.993(0.735-1.342)			0.96
Met.lung	501(11.7)	0.917(0.827 - 1.018)			•••	0.10	Met.lung	0.928(0.825 - 1.044)		.	0.21
B	(/)		-			٦				TT I	0.21
			0.35	0.50 0.	71 1.0 1	.41		0	.044 0.088 0.177 0.354	0.707 1.41	10

Figure 2 Effect of different factors on prognosis. After adjusting for all factors, multi-factor Cox regression analyses were performed for OS and DSS, respectively, and forest plots were drawn. AC, adenocarcinoma; Adj.HR, adjusted hazard ratio; AJCC, American Joint Commission on Cancer; CI, confidence interval; DSS, disease-specific survival; Met., metastasis; MAC, mucinous adenocarcinoma; NOS, not otherwise specified; OS, overall survival; ref, reference; SRCC, signet ring cell carcinoma.

the occurrence of survival outcomes was investigated using univariate and multivariate Cox regression (Table S3). Interestingly, after controlling for confounding factors, bone metastases were still strongly correlated with prognosis compared to other metastases (*Figure 4*). Meanwhile, the multivariate regression results clearly showed a strong correlation with OS, including single/ unmarried marital status, 2016 diagnosis, overlap site, stage T3–T4, pathological grade III–IV, chemotherapy, and surgical treatment. In terms of the DSS, distinct and robust correlations with overlap site, stage T3–T4, chemotherapy, and surgical treatment were observed.

Subgroup analysis was performed in post-PSM patients, and interactions between age (P=0.01), radiotherapy

 Table 2 Multivariate Cox regression analysis of different metastatic sites

Mot type	HR (95% CI)						
wei.type	OS	DSS					
Met.liver	1.00 (0.95–1.05)	1.00 (0.95–1.06)					
Met.bone	1.10 (1.01–1.20)	1.18 (1.07–1.30)					
Met.brain	1.03 (0.79–1.33)	0.99 (0.74–1.33)					
Met.lung	0.92 (0.84–1.01)	0.93 (0.83–1.03)					

Met., metastasis; HR, hazard ratio; CI, confidence interval; OS, overall survival; DSS, disease-specific survival.

(P=0.02), chemotherapy (P=0.03), and bone metastasis for OS were detected (Figure S4). In addition, regarding DSS, there were interactions for age (P=0.006), T-stage (P=0.03), chemotherapy (P=0.006), and bone metastasis (Figure S5).

Discussion

To the best of our knowledge, while numerous studies have reported a poorer prognosis for bone metastases (18), this study is pioneering in exploring the prognostic differences of single lung, liver, bone, and brain metastases in gastric cancer. The present study was conducted primarily to evaluate the prognostic survival differences among single organ metastases at different sites in gastric cancer. The findings uncovered that among single organ metastases in gastric cancer, the liver was the most prevalent site, with brain metastases being the least common. Furthermore, bone metastases demonstrated the worst prognosis. Of particular note, in examining bone metastases, 68.6% were identified as poorly differentiated, consistent with prior research implicating a heightened tendency for poorly differentiated gastric cancers to disseminate to the bones (21). This study leveraged HRs and floating absolute risk, and revealed that distinct metastatic sites in gastric cancer carried their own prognostic implications. Notably, gastric cancer bone metastases exhibited the shortest DSS (HR, 1.181; 95% CI: 1.055-1.323; P=0.004). In addition, the sub-dataset of PSM with "post-boc randomization" further confirmed a poorer OS (HR, 1.167; 95% CI: 1.033-1.318; P=0.01) and DSS (HR, 1.277; 95% CI: 1.11-1.468; P<0.001) for bone metastases, reinforcing the credibility of the present study. Subgroup analyses were specifically conducted for bone metastases to evaluate potential interacting factors, such as age, pathological type, chemotherapy, and number of metastatic sites. Significant

interactions were observed between bone metastases and these factors. Indeed, surgical treatment is not routinely recommended for metastatic gastric cancer. However, opinions within the academic community diverge on this issue. The REGATTA phase III trial demonstrated that the combination of primary tumor resection and chemotherapy failed to improve patient survival (22). Conversely, the AIO-FLOT3 trial indicated favorable outcomes for patients with limited metastatic gastric cancer who underwent gastrectomy along with the resection of metastatic lesions following chemotherapy (23). In this study, surgical treatment (accounting for 8.2% of the total patients) was associated with improved OS and DSS. Notably, improved OS for patients after 2015 and improved DSS for patients in 2016 were observed, which was speculated to be attributed to the increasing utilization of targeted therapy and immunotherapy as adjunctive measures to conventional cytotoxic chemotherapy (24). Given the low incidence, the ESMO and the National Comprehensive Cancer Network guidelines do not endorse routine bone scintigraphy for gastric cancer patients during diagnosis or treatment, which may lead to the neglect of some cases (25). However, abnormally elevated bone alkaline phosphatase levels require particular attention as well as further investigation. Alkaline phosphatase is primarily produced by osteoblasts in bone. Elevated levels of alkaline phosphatase may indicate bone tissue damage or abnormal proliferation. In the case of cancerous bone metastases, cancer cells invading bone tissue may increase osteoblast activity in the bone marrow, leading to higher alkaline phosphatase levels in the blood. Blood alkaline phosphatase levels can thus be used as an indicator for assessing bone metabolic activity. This is clinically significant as it aids in the detection of bone metastasis and its influence on patient prognosis.

Regarding reasons for worse prognosis in gastric cancer with bone metastasis, gastric cancer bone metastasis, in addition to the primary changes caused by gastric cancer, can also lead to skeletal-related events, such as pathological fractures, paralysis, hematologic disorders, poor chemotherapy response, and pain, significantly impacting patients' quality of life and reducing their survival rates (26). Spine is the most common site of bone metastasis, with the pelvis, ribs, sternum, and the long bones of the limbs following in prevalence. Therefore, compared to other metastases, bone metastases are more likely to lead to skeletal-related events (SREs) and necessitate longer periods of bed rest (27). A study has also reported that patients with SREs have a shorter median survival time compared

Characteristics	n(%)	Unadj.HR (95%CI) for	os	P I	Interaction	P Characteristics	Unadj.HR (95%CI)	for DSS	P Int	eraction P
Age(ref=Age ≤60)						Age(ref=Age ≤60)			
Age ≤60	1399(32.0	6) 1.482(1.29,1.702)	I +	< 0.001	ref	Age ≤60	1.48(1.278,1.714)	I ++++	< 0.001	ref
61~70	1251(29.	1) 1.548(1.312,1.825)	•••••	< 0.001	0.69	61~70	1.537(1.277,1.849)	▶ ●●●	< 0.001	0.74
Age≥71	1647(38.	3) 1.13(0.964,1.325)	• ↓ •••••	0.13	0.02	Age≥71	0.971(0.791,1.191)		0.77	0.003
Sex			I.			Sex		1		
Female	1264(29.4	4) 1.256(1.082,1.459)		0.003	ref	Female	1.173(0.987,1.395)	H	0.07	ref
Male	3033(70.0	6) 1.336(1.199,1.488)	→→→	< 0.001	0.69	Male	1.381(1.224,1.559)	•••	< 0.001	0.22
Race			1			Race		1		
White	3138(73)) 1.357(1.227,1.501)		< 0.001	ref	White	1.332(1.187,1.495)	+++	< 0.001	ref
Black	609(14.2	1.313(0.993,1.737)	→	0.05	0.99	Black	1.401(1.031,1.905)	·•	0.03	0.59
Others	550(12.8	3) 1.164(0.923,1.467)	•••••	0.19	0.25	Others	1.231(0.957,1.583)	••••	0.10	0.61
Marital			1			Marital		1		
Married	2513(58.	5) 1.368(1.219,1.535)		< 0.001	ref	Married	1.403(1.232,1.597)	•••	< 0.001	ref
Divorced/Separated	449(10.4) 1.105(0.834,1.464)	•••••	0.48	0.19	Divorced/Separatec	1 0.961(0.686,1.346)	•••••	0.81	0.04
Single/Unmarried	666(15.5) 1.308(1.067,1.603)		0.01	0.77	Single/Unmarried	1.296(1.038,1.619)	••• •	0.02	0.62
Widowed/Others	669(15.6) 1.241(0.979,1.571)	₩	0.07	0.90	Widowed/Others	1.18(0.893,1.559)	•+••	0.24	0.63
Year of diagnosis	570/10.0	1 2 40(1 0 50 1 52)	1			Year of diagnosis	1 220/0 024 1 (41)	!	0.105	
2010	572(13.3) 1.349(1.058,1.72)		0.01	ref	2010	1.238(0.934,1.641)	⊷ ⊶•	0.137	ref
2011	647(15.1) 1.563(1.245,1.963)	, 	<0.001	0.54	2011	1.614(1.245,2.093)	, ⊷ ⊶	< 0.001	0.27
2012	633(14.7	1.256(1.021,1.546)		0.03	0.64	2012	1.2/(1.006,1.602)	••• •	0.04	0.92
2013	671(15.6	(0.971, 1.494)	+	0.09	0.37	2013	1.282(1.01,1.627)		0.04	0.98
2014	6/3(15.7) 1.464(1.174,1.825)		<0.001	0.73	2014	1.569(1.228,2.005)		< 0.001	0.26
2015	693(16.1) 1.266(1.024,1.564)		0.02	0.55	2015	1.133(0.884,1.452)	HHH	0.32	0.54
2016	408(9.5)) 1.11(0.75,1.64)		0.60	0.33	2016	1.089(0.697,1.702)	• • •••••	0.70	0.56
Primary site	1024/44	0) 1 2(2(1 102 1 572)	1	.0.001	c	Primary site	1 270(1 175 1 (17)	1	.0.001	c
Cardia/Fundus	1924(44.3	8) 1.363(1.183,1.572)		< 0.001	ref	Cardia/Fundus	1.3/9(1.1/5,1.61/)		< 0.001	ref
Antrum/Pylorus	6/4(15.7) 1.4/1(1.164,1.859)		0.001	0.27	Antrum/Pylorus	1.448(1.109,1.89)		0.006	0.42
Body	3//(8.8)	1.39(1.05,1.841)		0.02	0.59	Body	1.415(1.024,1.955)		0.03	0.61
Greater cur vature	12/(3)	0.894(0.538,1.486)		0.66	0.13	Greater curvature	0./99(0.432,1.478)		0.47	0.08
Lesser curv ature	256(6)	1.268(0.873,1.842)		0.21	0.79	Lesser curvature	1.162(0.745,1.811)		0.50	0.54
NOS	641(14.9) 1.04(0.858,1.26)		0.69	0.05	NOS	1.05/(0.852,1.311)		0.61	0.11
Overlap	298(6.9)	1.117(0.822,1.517)		0.48	0.31	Overlap	1.141(0.81,1.606)	•••••	0.45	0.38
AJCC.1	072(22.0) 1 225(1 012 1 494)	i i	0.02	c	AJCC.T	1 222(1 0(0 1 (27)	i, a	0.01	c
10-2	9/3(22.0	$\begin{array}{c} 0 \\ 1.225(1.012, 1.484) \\ 0 \\ 1.262(1.151, 1.614) \end{array}$		0.03	rei	10-2 T2 4	1.322(1.009, 1.037) 1.25((1.12, 1.(42))		0.01	rei
13-4 To 9 University	1201(27.)	9) 1.303(1.131,1.014) 4) 1.221(1.17,1.401)		<0.001	0.54	1 3 ⁻⁴ T.: 0 I.I.: I.:	1.330(1.12,1.043)		0.002	0.97
A LCC N	2125(49.	+) 1.321(1.17,1.491)		<0.001	0.05	A LCC N	1.2/9(1.114,1.408)	1	<0.001	0.71
AJUU.N NO-1	2882(67	1) 1 205(1 166 1 44)		<0.001	nof	AJCC.N NO-1	1 201(1 155 1 465)	1.000	<0.001	nof
NO 1 N2_2	405(07.	1) 1.295(1.100, 1.44) 1 $117(1.065, 1.886)$		<0.001 0.01	0.72	NO 1 N2_2	1.501(1.155,1.405)		<0.001 0.01	0.51
Nz 5	1000(22	(1.417(1.005, 1.000))		0.01	0.75	Nz J	1.300(1.089,2.082)		0.01	0.51
Crada	1009(23.	5) 1.521(1.095,1.595)		0.004	0.92	Crada	1.202(1.010,1.500)		0.05	0.75
I all	1157(26)	0) 1 421(1 005 1 872)	· · · · · · · · · · · · · · · · · · ·	0.000	rof		1 20(0 034 1 783)	i	0.122	rof
III.IV	2303(53)	(1.077137)		<0.009	0.25	III~IV	1.108(1.06.1.354)		0.122	0.60
Unknown	837(10 5	(1) 1 284(1062 1552)		0.001	0.25	Unknown	1 287(1 041 1 59)		0.004	0.02
Radiation	057(17.5) 1.204(1.002,1.332)		0.01	0.70	Radiation	1.207(1.011,1.35)		0.02	0.02
No/Unknown	3369(78)	4) 1 265(1 135 1 41)		<0.001	ref	No/Unknown	1 286(1 138 1 454)		< 0.001	ref
Ves	928(21.6	1, 1.205(1.155, 1.41)		<0.001	0.29	Ves	1.200(11130,11131)		<0.001	0.74
Chemotherany	20(21.0) 1.17(1.25),1.715)		-0.001	0.27	Chemotherany	1.100(1.10,1.070)	i terretari	-0.001	0.71
No	1478(34	4) 1 162(1 004 1 346)		0.045	ref	No	1 026(0 861 1 223)	<u> </u>	0.776	ref
Yes	2819(65)	6) 1 492(1 337 1 664)		<0.015	0.05	Yes	1 565(1 388 1 765)		<0.001	0.001
Surgery	2017(05.	0) 1.472(1.557,1.004)		-0.001	0.05	Surgery	1.505(1.500,1.705)	i i	-0.001	0.001
No/Unknown	3944(91 9	8) 1 288(1 177 1 409)		<0.001	ref	No/Unknown	1 285(1 161 1 423)		<0.001	ref
Ves	353(8.2)	1 409(0 964 2 059)		0.001	0 70	Ves	1 393(0 895 2 17)		0.14	0.73
Histological type(r	$f=\Lambda(C)$	1.109(0.901,2.039)	1	0.07	0.70	Histological type	(ref=AC)	1	0.11	0.75
AC	3084(71)	8) 1 37(1 217 1 542)		<0.001	ref	AC	1316(1151507)		<0.001	ref
MAC/SRCC	650(15.1	0.0007(0.844.1.177)		0.001	0.002	MAC/SRCC	1.063(0.883.1.281)		0.51	0.05
Others	563(13.1) 1 528(1 166 2 002)		0.002	0.002	Others	1 532(1 114 2 107)		0.009	0.03
Numbers of sites/r	ef=1)	,		0.002	0.57	Numbers of sites	(ref=1)		0.007	0.55
1	3459(80	5) 1 288(1 168 1 421)		< 0.001	ref	1	1 285(1 162 1 421)		<0.001	ref
>2	838(19.5	(1.1200(1.100,1.121))		<0.001	0.31	>2	3 38(1 829 6 246)		→ <0.001	0.006
		· · · · · · · · · · · · · · · · · · ·			5.51		2.20(1.02),0.2 (0)		0.001	0.000
		0.50	0.71 1.0 1.41 2	.0				0.50 1.0 2.0 4.0		

Figure 3 Cox regression analysis of different subgroups of bone metastases. Univariate Cox regression analysis was performed among different subgroups for bone metastases. We calculated the interaction between subgroups and bone metastasis and plotted the forest plot. AC, adenocarcinoma; AJCC, American Joint Commission on Cancer; CI, confidence interval; DSS, disease-specific survival; NOS, not otherwise specified; MAC, mucinous adenocarcinoma; OS, overall survival; ref, reference; SRCC, signet ring cell carcinoma; Unadj.HR, unadjusted hazard ratio.

to those without SREs, which may thus contribute to a poorer prognosis (15). Additionally, tumor invasion of the bone can cause hematological abnormalities and even trigger disseminated intravascular coagulation, leading to rapid disease progression and death (28). Current research suggests that bone metastasis affects the function of osteoblasts and osteoclasts, leading to either osteolytic destruction or osteoblastic proliferation (29). Besides, tumor cell proliferation produces factors such as IL-6 and parathyroid hormone-related peptide (PTHrP), which

Characteristics	n(%)	Adj.HR (95%CI) fo	r OS	P value	Characteristics	Adj.HR (95%CI) fof DSS		P value
Age(ref=Age ≤60)					Age(ref=Age ≤60))		
61~70	338(27.9)	1.088(0.933-1.268)	+++++++++++++++++++++++++++++++++++++++	0.28	61~70	0.971(0.818-1.151)	+0+	0.73
Age ≥71	380(31.4)	1.076(0.912-1.269)	⊷ ∔ ⊕ ⊶	0.38	Age ≥71	1.017(0.845-1.223)	••••	0.86
Sex(ref=Female)			i		Sex(ref=Female)		i	
Male	792(65.5)	1.003(0.875-1.149)		0.97	Male	1.051(0.9-1.228)	+0+	0.52
Race(ref=White)			1		Race(ref=White)			
Black	132(10.9)	1.145(0.934-1.403)	+	0.19	Black	1.202(0.963-1.501)		0.10
Others	177(14.6)	0.86(0.715-1.034)	⊷ ⊷∔	0.10	Others	0.884(0.722-1.082)		0.23
Marital(ref=Marri	ied)	· · · · · ·			Marital(ref=Mar	ried)	i i	
Divorced/Separated	117(9.7)	0.868(0.697-1.082)	→	0.20	Divorced/Separated	0.886(0.689-1.139)		0.34
Single/Unmarried	222(18.3)	1.194(1.01-1.413)		0.03	Single/Unmarried	1.118(0.931-1.343)	++++	0.23
Widowed/Others	204(16.9)	0.932(0.777-1.118)	• ••• •••	0.44	Widowed/Others	0.943(0.76-1.171)		0.59
Year of diagnosis(ref=2010)	· /	1		Year of diagnosis	(ref=2010)		
2011	159(13.1)	1.112(0.885-1.396)	,	0.36	2011	1.153(0.89-1.494)	++++++	0.28
2012	196(16.2)	0.929(0.748-1.154)	• ••• •	0.50	2012	0.943(0.738-1.204)		0.63
2013	185(15.3)	0.852(0.682-1.064)		0.15	2013	0.78(0.608-1.001)	H	0.05
2014	181(15)	0.966(0.771-1.21)	• - ••	0.76	2014	0.926(0.719-1.192)	⊷ ∎⊷	0.55
2015	212(17.5)	0.906(0.727 - 1.13)	•••• <u>•</u> ••	0.38	2015	0.89(0.694 - 1.141)		0.36
2016	109(9)	0.612(0.429 - 0.873)		0.007	2016	0.677(0.453 - 1.014)	—	0.05
Primary site(rof-C	'ordio/Fun	due)			Primary site(ref=	Cardia/Fundus)		
Antrum/Pylorus	163(13.5)	1.111(0.905-1.363)	•••••	0.31	Antrum/Pylorus	1.065(0.84 - 1.35)		0.60
Body	113(9.3)	1152(0909-1461)		0.24	Body	1 056(0 799-1 396)		0.70
Greater curvature	44(3.6)	0.991(0.699-1.406)		0.96	Greater curvature	0.897(0.595-1.351)		0.60
Lesser curvature	78(6.4)	1.191(0.908 - 1.562)		0.20	Lesser curvature	1 175(0 859-1 607)		0.31
NOS	246(20.3)	1.151(0.93-1.337)		0.23	NOS	1.185(0.968 - 1.451)		0.10
Overlan	101(8.3)	$1.115(0.95 \ 1.557)$ 1.41(1.107 - 1.796)		0.005	Overlan	1.5(1.153 - 1.951)		0.002
AJCC.T(ref=T0-2	3	1.41(1.107 1.750)		0.000	AJCC.T(ref=T0-	2)		0.002
T3-4	327(27)	1 227(1 021-1 475)	••••	0.02	T3-4	1459(1181 - 1803)	i 🛶	< 0.001
Tx&Unknown	636(52.6)	1.404(1.186 - 1.662)	· • • • • •	< 0.001	Tx&Unknown	1 547(1 271-1 882)	L	< 0.001
AJCC.N(ref=N0-1	000002.0)				AJCC.N(ref=N0-	-1)		
N2-3	109(9)	1 019(0 805-1 29)		0.87	N2-3	0.951(0.724 - 1.248)		0.71
Ny Ny	286(23.6)	1.069(0.886-1.29)		0.48	Nx	0.958(0.775 - 1.184)		0.69
Grade(ref=L~II)	200(25.0)	1.009(0.000 1.29)		0.10	Grade(ref=I~II)	0.950(0.775 1.101)		0.07
III~IV	829(68.5)	1 248(1 007-1 545)		0.04		1 275(0 993-1 635)		0.05
Unknown	256(21.2)	1 182(0 928-1 506)		0.17	Unknown	1.284(0.97-1.7)		0.05
Radiation(ref=No/	Unknown)	1.102(0.920 1.500)	1	0.17	Radiation(ref=No	/Unknown)		0.00
Ves	410(33.9)	1 101(0 96-1 262)		0.17	Ves	1.058(0.906 - 1.236)		0.47
Chemotherany(ref	+10(55.7) =No)	1.101(0.90 1.202)		0.17	Chemotherany(re	n.056(0.900 1.250)		0.47
Ves	776(64.1)	0 369(0 319-0 427)	· ·	< 0.001	Vec	0.297(0.25-0.353)		< 0.001
Surgery(ref=Ne/II	nknown)	0.507(0.517 0.427)		< 0.001	Surgery(ref-No/I	(0.257(0.2570.555)		< 0.001
Vac	62(5.1)	0 522(0 270-0 722)	· · · · · · · · · · · · · · · · · · ·	< 0.001	Vac	0.454(0.312-0.66)	i	< 0.001
Histological type(r	of = AC	0.525(0.579 0.725)		< 0.001	Histological type	(rof = AC)		< 0.001
MAC/SBCC	205(22 G)	1 015(0 979 1 172)		0.84	MAC/SBCC	0.024(0.706 1.007)	-	0.40
MAC/SRCC	122(10.1)	1.013(0.878 - 1.173)		0.04	MAC/SRCC	0.934(0.790-1.097)		0.40
Numbers	122(10.1) f=1)	0.809(0.049-1.009)		0.00	Numbers	0.705(0.544-0.915)		0.008
Numbers of sites(re	252(20 C)	0.956(0.729 1.005)		0.05	vullbers of sites		i	< 0.001
<u></u> Matterna (255(20.9)	0.830(0.728-1.005)		0.05	<u><-</u> Mot tune (nof-M)	ot others)	1	~ 0.001
Methods (rei=Met	.otners)	1 167(1 022 1 219)		0.01	Mathana	1 277(1 11 1 468)		< 0.001
iviet.bone	005(50)	1.10/(1.055-1.518)		0.01	wiet.bone	1.277(1.11=1.408)	 	~ 0.001
		0	.35 0.50 0.71 1.0 1.41 2	.0		0.044 0.088 0	.177 0.354 0.707 1.410	1

Figure 4 Results of multivariate Cox regression analysis after PSM. In the post-PSM cohort, we adjusted all variable factors, performed multivariate Cox regression analysis for OS and DSS separately, and plotted the forest plot. AC, adenocarcinoma; Adj.HR, adjusted hazard ratio; AJCC, American Joint Commission on Cancer; CI, confidence interval; DSS, disease-specific survival; Met., metastasis; Met.others, metastasis to lung, liver, brain; MAC, mucinous adenocarcinoma; NOS, not otherwise specified; OS, overall survival; ref, reference; SRCC, signet ring cell carcinoma; PSM, propensity score matching.

activate the receptor activator of nuclear factor kappa-b ligand pathway and stimulate osteoclast proliferation (30). In addition to osteolytic lesions, bone metastasis often induces sclerotic proliferation. Bone proliferative diseases are also associated with abnormalities in the number and function of osteoblasts and osteoclasts. On one hand, tumor cells release endothelin-1 to inhibit osteoclast movement (31). Additionally, the BB isoform, a subtype of plateletderived growth factor secreted by tumor cells, has been found to stimulate osteoblast activation and promote bone proliferation (32). On the other hand, osteoblasts express osteoprotegerin and hepatocyte growth factors, thereby promoting tumor cell survival (33). In addition to bone cells, endothelial cells in the bone marrow not only provide an adhesive surface for tumor cells entering the bone (34), but can also be induced to produce growth factors and PTHrP, which are involved in the process of angiogenesis (35).

Herein, over half of the patients in the study sample

received chemotherapy, and the management of SRE symptoms was considered equally important. Besides, a significant interaction between bone metastases and gastric cancer pathological types was observed. Previous studies have reported that the preferred site of metastasis varies for different subtypes of breast cancer (36-39). Additionally, the ccA/ccB subtype of clear cell renal cell carcinoma has been documented to be significantly associated with the location and grading of metastatic cancer (20). These findings are comparable to the present observations. The pain experienced by patients with bone metastasis severely affects their quality of life. Analgesic opioids or radiation therapy (more commonly used for neuropathic pain) can be considered (40). In this study sample, radiation therapy was administered to 36.9% of patients, representing the largest proportion after those with brain metastasis. This group of patients receiving radiation therapy likely encompassed those treated for both tumor control and pain management. Additionally, due to the active function of osteoclasts in patients with bone metastasis, bisphosphonate drugs can not only inhibit their function but also induce tumor cell apoptosis and inhibit bone metastasis (41). The underlying mechanisms are still under exploration. In general, therefore, even if patients are diagnosed with stage M1 gastric cancer, it remains essential to conduct a comprehensive assessment of factors such as histological type, age, site of metastasis, and number of metastases to formulate personalized treatment strategies.

Despite the relatively longer progression time of metastases in other sites such as the liver, brain, and lungs compared to bone metastasis, their median survival time still does not exceed six months. However, it is reassuring that the prognostic differences among various metastatic sites are being increasing clarified. Further research will be conducted to actively and specifically monitor these patients with targeted follow-up to offer novel insights into future treatments. Overall, this study reinforces the notion that the prognosis varies among different metastases of gastric cancer. This finding is expected to provide physicians with the tools to more accurately assess patient prognoses. Meanwhile, it can also empower patients with a clearer understanding of their disease status, enhance their quality of life, and reduce their suffering.

However, this study still has the following main limitations: first, the study lacked access to more detailed patient information, such as patients' transcriptomic features, relevant imaging data, and hematological tumor markers. While a relatively poorer prognosis for bone metastasis was predicted, reasons for its worse prognosis were not clarified, significantly hampering further research. Besides, it should be noted that this study was conducted on a specific population-based cohort. While the underlying pathology and physiology of the disease may be consistent across different groups, variations in lifestyle, environment, and genetics should still be taken into account, necessitating further validation of these conclusions. Prospective research should be also pursued to investigate the detailed reasons for poorer prognosis. Lastly, acknowledging the paramount importance of quality of life for patients in the advanced stages of cancer, future research should also consider incorporating quality of life as an important efficacy reference. There are still several questions to be answered. A natural progression of this work will be to analyze the prognosis of different sites of gastric cancer metastasis. From a broader perspective, means and methods for early detection of bone metastasis should be further identified. Significant efforts are also required to elucidate the mechanisms of gastric cancer metastasis, and the issue of metastasis poses an intriguing question to be explored in further studies. Moreover, studying the pathological and signaling pathway alterations following metastasis may contribute to establishing higher accuracy in this field.

Conclusions

In conclusion, this study elucidates the prognostic differences in single organ metastases of gastric cancer, offers insights into subsequent clinical treatment, and lays the groundwork for exploring the mechanisms of single organ metastasis in gastric cancer.

Acknowledgments

Funding: This work was supported by the Guangxi Natural Science Foundation (No. 2023GXNSFBA026006), the Special Fund of the Central Government Guiding Local Scientific and Technological Development by Guangxi Science and Technology Department (GuikeZY21195024), the Research Capability Improvement Project for Young and Middle-aged Teachers in in Guangxi Universities (No. 2023KY0510), and the Innovation Project of Guangxi Graduate Education (No. YCSW2023422).

Footnote

Reporting Checklist: The authors have completed the

STROBE reporting checklist. Available at https://tgh. amegroups.com/article/view/10.21037/tgh-24-11/rc

Peer Review File: Available at https://tgh.amegroups.com/ article/view/10.21037/tgh-24-11/prf

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tgh.amegroups.com/article/view/10.21037/tgh-24-11/coif). H.N.G. reports funding supports from the Guangxi Natural Science Foundation, and the Research Capability Improvement Project for Young and Middle-aged Teachers in Guangxi Universities. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The Ethics Committee of The Affiliated Hospital of Guilin Medical University waived the requirement for formal Institutional Review Board approval and informed consent, given its use of anonymous data and supplementary information obtained from individuals.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

- Thrift AP, El-Serag HB. Burden of Gastric Cancer. Clin Gastroenterol Hepatol 2020;18:534-42.
- Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol 2023;20:338-49.
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49.

- 4. Sexton RE, Al Hallak MN, Diab M, et al. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev 2020;39:1179-203.
- Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33:1005-20.
- 6. Kwee RM, Kwee TC. Modern imaging techniques for preoperative detection of distant metastases in gastric cancer. World J Gastroenterol 2015;21:10502-9.
- Koizumi M, Yoshimoto M, Kasumi F, et al. Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 2003;14:1234-40.
- Li Q, Wang Y, Cai G, et al. Solitary lymph node metastasis is a distinct subset of colon cancer associated with good survival: a retrospective study of surveillance, epidemiology, and end-results population-based data. BMC Cancer 2014;14:368.
- Okano K, Maeba T, Ishimura K, et al. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 2002;235:86-91.
- Fuchs J, Früh M, Papachristofilou A, et al. Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients - evaluation of outcome and prognostic factors: A retrospective multicenter study. PLoS One 2021;16:e0253601.
- Acciuffi S, Meyer F, Bauschke A, et al. Solitary colorectal liver metastasis: overview of treatment strategies and role of prognostic factors. J Cancer Res Clin Oncol 2022;148:657-65.
- Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
- 13. Maccauro G, Spinelli MS, Mauro S, et al. Physiopathology of spine metastasis. Int J Surg Oncol 2011;2011:107969.
- Liang Y, Zhang H, Song X, et al. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol 2020;60:14-27.
- Petrillo A, Giunta EF, Pappalardo A, et al. Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them. J Clin Med 2021;10:1777.
- Ciner AT, Jones K, Muschel RJ, et al. The unique immune microenvironment of liver metastases: Challenges and opportunities. Semin Cancer Biol 2021;71:143-56.
- 17. Fuchs CS. Chemotherapy for advanced gastric cancer: where do we stand? J Clin Oncol 1997;15:3299-300.
- Riihimäki M, Hemminki A, Sundquist K, et al. Metastatic spread in patients with gastric cancer. Oncotarget 2016;7:52307-16.
- 19. Neville AM, Bettelheim R, Gelber RD, et al. Factors

Page 14 of 14

predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992;10:696-705.

- 20. Serie DJ, Joseph RW, Cheville JC, et al. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. Eur Urol 2017;71:979-85.
- Qiu MZ, Shi SM, Chen ZH, et al. Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: A SEER-based study. Cancer Med 2018;7:3662-72.
- 22. Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016;17:309-18.
- 23. Al-Batran SE, Homann N, Pauligk C, et al. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncol 2017;3:1237-44.
- 24. Zeng Y, Jin RU. Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer. Semin Cancer Biol 2022;86:566-82.
- Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v38-49.
- 26. Kim YJ, Kim SH, Kim JW, et al. Gastric cancer with initial bone metastasis: a distinct group of diseases with poor prognosis. Eur J Cancer 2014;50:2810-21.
- 27. Silvestris N, Pantano F, Ibrahim T, et al. Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. PLoS One 2013;8:e74402.
- Gomi D, Fukushima T, Kobayashi T, et al. Gastric cancer initially presenting as bone metastasis: Two case reports and a literature review. Oncol Lett 2018;16:5863-7.
- 29. Roodman GD. Mechanisms of bone metastasis. N Engl J

doi: 10.21037/tgh-24-11

Cite this article as: Zhao QW, Quan Z, Liu SS, Wang YD, Guo HN. Heterogeneity and prognosis of single organ metastases in gastric cancer. Transl Gastroenterol Hepatol 2024;9:61.

Med 2004;350:1655-64.

- de la Mata J, Uy HL, Guise TA, et al. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 1995;95:2846-52.
- Mohammad KS, Guise TA. Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop Relat Res 2003;(415 Suppl):S67-74.
- Achbarou A, Kaiser S, Tremblay G, et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994;54:2372-7.
- Vallet S, Bashari MH, Fan FJ, et al. Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/ MET Pathway. PLoS One 2016;11:e0150507.
- 34. Esposito M, Kang Y. Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther 2014;141:222-33.
- 35. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5.
- Molnár IA, Molnár BÁ, Vízkeleti L, et al. Breast carcinoma subtypes show different patterns of metastatic behavior. Virchows Arch 2017;470:275-83.
- 37. Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008;68:3108-14.
- Ignatov A, Eggemann H, Burger E, et al. Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol 2018;144:1347-55.
- Grote I, Poppe A, Lehmann U, et al. Frequency of genetic alterations differs in advanced breast cancer between metastatic sites. Genes Chromosomes Cancer 2024;63:e23199.
- 40. Rich SE, Chow R, Raman S, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol 2018;126:547-57.
- Roelofs AJ, Thompson K, Ebetino FH, et al. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 2010;16:2950-60.